TrialThe Lancet. Infectious diseases2023

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.

Jing-Xin Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.